Clearmind Medicine Inc. - Common Shares (CMND)
0.4585
+0.00 (0.00%)
NASDAQ · Last Trade: Nov 12th, 6:52 AM EST
Via Benzinga · November 12, 2025
The regular session of the US market on Tuesday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.
Via Chartmill · November 11, 2025
Via Benzinga · November 11, 2025
Intrigued by the market activity one hour before the close of the markets on Tuesday? Uncover the key winners and losers of today's session in our insightful analysis.
Via Chartmill · November 11, 2025
Curious about what's happening in today's session? Check out the latest stock movements and price changes.
Via Chartmill · November 11, 2025
Via Benzinga · November 11, 2025
Shares of Clearmind Medicine Inc. (NASDAQ: CMND) are falling Friday after the clinical-stage biotech company shared a key update about its stock listing.
Via Benzinga · November 7, 2025
Via Benzinga · November 6, 2025
In today's session, these stocks are experiencing unusual volume.
Via Chartmill · October 31, 2025
Before the US market kicks off on Friday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.
Via Chartmill · October 31, 2025
Via Benzinga · September 22, 2025
Via Benzinga · September 19, 2025
The market is filled with gapping stocks in Friday's session. Let's discover which stocks are showing gap-ups and gap-downs.
Via Chartmill · September 19, 2025
Via Benzinga · August 28, 2025
In today's session, there are stocks attracting attention with their unusual volume. Let's take a closer look.
Via Chartmill · April 21, 2025

SciSparc Ltd (NASDAQ:SPRC) shares are ripping higher Monday after the company announced that its collaboration with Clearmind Medicine Inc (NASDAQ:CMND) led to a patent application for psychedelic therapy targeting cocaine addiction.
Via Benzinga · March 10, 2025

SciSparc teams up with Clearmind Medicine on innovative therapies for binge behaviors and secures FDA approval for a Tourette Syndrome Phase 2b trial.
Via Benzinga · January 6, 2025

Clearmind Medicine's stock rose 63.9% after receiving IRB approval for its Phase I/IIa trial of CMND-100, a drug for alcohol use disorder.
Via Benzinga · December 24, 2024

Via Benzinga · October 11, 2024

Clearmind Medicine filed an international patent for a treatment that aims to enhance addiction treatment safety and efficacy.
Via Benzinga · September 17, 2024

Clearmind Medicine secures a U.S. patent for its MEAI-based binge behavior treatment, marking a significant advancement in addressing Alcohol Use Disorder.
Via Benzinga · August 23, 2024

We have all of the biggest pre-market stock movers that traders need to know about on Friday with the latest news breakdowns!
Via InvestorPlace · August 9, 2024


